Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Agenus
Biotech
BMS oncology head swings to Syndax—Chutes & Ladders
BMS oncology head swings to Syndax. Stylus unsheathes with Bayer vet at helm. T1D Fund picks up former BMS dealmaker.
Darren Incorvaia
,
Zoey Becker
May 16, 2025 8:30am
Incyte exits cancer pact, leaving Agenus weighing its options
Feb 11, 2025 7:55am
Bristol Myers culls cell therapy deals with 2 biotechs
Dec 16, 2024 11:19am
BMS ditches TIGIT, ending $200M bet on Agenus bispecific
Aug 5, 2024 9:17am
FDA wrecks Agenus’ accelerated approval plan
Jul 18, 2024 8:01am
BMS trims anti-TIGIT and a handful of other meds
Sep 14, 2023 1:57pm